目的 觀察北京燕化醫(yī)院2011-2014年防治慢性乙型肝炎藥物的使用情況,為抗肝炎藥物的臨床合理應用提供依據(jù)。方法 統(tǒng)計該院2011-2014年住院與門診患者防治慢性乙肝藥物的使用情況、藥物種類及用藥頻度(DDDs)、日均費用(DDC)等,并對安全性及耐藥性進行總結(jié)與分析。結(jié)果 該院常用的防治慢性乙型肝炎藥物主要為干擾素與核苷(酸)類,核苷類藥物所占比例較大,在2011-2014年中藥品構成排序發(fā)生變化,由于拉夫米定的耐藥性導致其使用率逐漸下降,恩替卡韋使用率逐漸上升,阿福韋德使用率上升后降低。結(jié)論 抗病毒治療成為防治慢性乙型肝炎的重要方法,應該結(jié)合藥物特點及患者實際情況,合理規(guī)范使用干擾素及核苷(酸)類藥物,優(yōu)化治療方案,加強臨床耐藥管理,降低藥物耐藥率。

Objective To observe the clinical use of anti-hepatitis therapy on chronic hepatitis B in Beijing Yanhua Hospital in 2011-2014, in order to provide basis for the rational administration of anti-hepatitis drugs. Methods The application of anti-hepatitis therapy on chronic hepatitis B in Beijing Yanhua Hospital in 2011-2014 were recorded, including the drug type and frequency of use and costs, irrational drug use prevention and treatment of chronic hepatitis cases are classified statistics. Results The interferon and nucleoside (acid) category were used primarily for prevention and treatment of chronic hepatitis B of our hospital in 2011-2014, nucleoside drugs had a larger proportion. Medicines constitute ordering changed in 2011-2014, due to lamivudine resistance led to decreased utilization; Entecavir utilization increased gradually, Fu Wade usage increased after lowering. Conclusion It shows that antiviral therapy has become an important method for the prevention and treatment of chronic hepatitis B, and the drug should be combined with patient characteristics and actual situation. The reasonable and standard usage of interferon and nucleoside (acid), optimization of treatment options, clinical resistance management and reduction of drug resistance should be performed.